Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

85.84B

Market cap85.84B

Price-Earnings ratio

20.43

Price-Earnings ratio20.43

Dividend yield

0.44%

Dividend yield0.44%

Average volume

736.84K

Average volume736.84K

High today

$836.58

High today$836.58

Low today

$825.00

Low today$825.00

Open price

$829.13

Open price$829.13

Volume

204.77K

Volume204.77K

52 Week high

$844.92

52 Week high$844.92

52 Week low

$541.00

52 Week low$541.00

Stock Snapshot

With a market cap of 85.84B, Regeneron(REGN) trades at $833.75. The stock has a price-to-earnings ratio of 20.43 and currently yields dividends of 0.44%.

As of 2026-08-21, Regeneron(REGN) stock has fluctuated between $825.00 and $836.58. The current price stands at $833.75, placing the stock +1.1% above today's low and -0.3% off the high.

Regeneron(REGN) shares are trading with a volume of 204.77K, against a daily average of 736.84K.

During the past year, Regeneron(REGN) stock moved between $541.00 at its lowest and $844.92 at its peak.

REGN News

TipRanks 2h

Regeneron Stock Buckling as Shareholders Sue Over Cancer Drug Claims

A class action lawsuit was filed against biotechnology company Regeneron (REGN) on July 16, which could put further pressure on its troubled share price. The pl...

TipRanks 21h

Regeneron’s Olatorepatide Trial Signals a Bid for Obesity Market Upside - TipRanks

...

Simply Wall St 21h

Regeneron Pharmaceuticals Wins FDA Approval For The First Adult FOP Treatment

Regeneron Pharmaceuticals (NasdaqGS: REGN) received FDA approval for Pasatru (garetosmab-grts) as the first treatment for adults with fibrodysplasia ossificans...

Analyst ratings

60%

of 30 ratings

Buy

60%

Hold

33.3%

Sell

6.7%

More REGN News

TipRanks 1d

Regeneron’s Pasatru granted FDA approval for FOP

The U.S. Food and Drug Administration has approved Pasatru to reduce new heterotopic ossification and reduce clinician-assessed disease flare-ups in adults with...

TipRanks 4d

Regeneron price target raised to $824 from $641 at Leerink

Leerink analyst David Risinger raised the firm’s price target on Regeneron (REGN) to $824 from $641 and keeps a Market Perform rating on the shares. Unlock pow...

Nasdaq 7d

GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)

Key Points Amgen is developing a highly differentiated GLP-1 product. Regeneron has a pair of promising GLP-1 candidates in the pipeline. Both biotechs are p...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.